Isoliquiritigenin Suppresses Breast Tumor Development by Enhancing Host Antitumor Immunity

Area of Science:

• Immunology
• Pharmacology
• Molecular Biology

Background:

• Isoliquiritigen (ISL), a licorice compound, exhibits antitumor properties.
• ISL's efficacy varies between immunocompetent and immunocompromised models.
• The mechanism underlying ISL's immune-mediated effects requires elucidation.

Purpose of the Study:

• To investigate the mechanism of ISL's antitumorigenic effects, focusing on immune response.
• To determine the role of PD-L1 and miR-200c in ISL-mediated breast cancer suppression.
• To evaluate the synergistic effect of ISL with paclitaxel.

Main Methods:

• Comparative analysis of ISL efficacy in immunocompetent versus immunocompromised mice.
• Assessment of CD8 T cell infiltration and PD-L1 expression in tumors.
• Quantitative real-time PCR and Western blot to analyze miR-200c, ZEB1/2, and PD-L1 levels.
• Functional assays using antagomiRs and siRNA/shRNA to confirm molecular targets.
• Investigation of ERK and Src signaling pathways.
• Evaluation of ISL and paclitaxel combination therapy in a murine breast tumor model.

Main Results:

• ISL demonstrated superior breast tumor suppression in immunocompetent mice, correlated with increased CD8 T cell infiltration.
• ISL treatment significantly reduced PD-L1 expression in both tumor tissues and cancer cells.
• ISL selectively upregulated miR-200c, which targets PD-L1 mRNA via the miR-200c/ZEB1/2 axis.
• ISL inhibited PD-L1 by concurrently targeting ERK and Src signaling pathways.
• Combination therapy with ISL and paclitaxel exhibited enhanced tumoricidal effects.

Conclusions:

• ISL-mediated tumor suppression is driven by the augmentation of host antitumor immunity.
• The miR-200c/ZEB1/2 pathway and PD-L1 downregulation are critical components of ISL's mechanism.
• ISL holds potential as an immunotherapeutic agent for breast cancer, particularly in combination therapies.